The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE.
Thomas Denis Bachelot
Consultant or Advisory Role - Roche
Research Funding - Roche
Eva Ciruelos
No relevant relationships to disclose
Tamar Peretz-Yablonski
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Fabio Puglisi
Consultant or Advisory Role - Roche
Honoraria - Roche
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Medac; Roche
Honoraria - AstraZeneca; Celgene; Eisai; GlaxoSmithKline; Novartis; Roche
Research Funding - Celgene; Roche
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Bruno P. Coudert
Consultant or Advisory Role - Amgen; Genomic Health; Lilly; Pfizer; Roche
Bella Kaufman
Consultant or Advisory Role - Roche
Honoraria - Roche
Andrew M. Wardley
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
Lydie Bastiere-Truchot
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ulrich Freudensprung
Employment or Leadership Position - Roche
Eleonora Restuccia
Employment or Leadership Position - Roche
David Miles
Honoraria - Roche